Correlation between HIV inhibiting drugs activity in human macrophages and clinical outcome;Attivita di farmaci inhibitor del virus dell'immunodeficienza umana in macrofagi umani e correlazione con l'efficacia clinica

Clinica Terapeutica

Volumn 149, Issue 1, 1998, Pages 37-41

  Aquaro, S ^a   Balestra, E ^a   Panti, S ^a   Cenci, A ^a   Serra, F ^a   Francesconi, M ^b   Abdelahad, D ^b   Calio R ^a   Perno, C F ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Ospedale di Frascati   (Italy)

Author keywords

AIDS; Drugs; Efficacy; HIV; Lymphocytes; Macrophages

Indexed keywords

1 (NAPHTHOXYACETYL)HISTIDYL(5 AMINO 6 CYCLOHEXYL 3,4 DIHYDROXY 2 ISOPROPYLHEXANOYL)ISOLEUCINE N (2 PYRIDYLMETHYL)AMIDE; ADEFOVIR; DIDANOSINE; LAMIVUDINE; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL CULTURE; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE; MACROPHAGE; VIRUS INHIBITION; VIRUS REPLICATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; MALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HUMANS; MACROPHAGES; MALE; ZIDOVUDINE;

EID: 0031626372     PISSN: 00099074     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Barrè-Sinoussi F, Chermann JC, Rey F, et al.: Isolation of a T-cell lymphotropic virus from a patient at risk for the acquired immunodeficiency syndrome (AIDS). Science 220: 868-871, 1983
2. Gartner S, Markovits P, Markovitz DM, et al.: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 233:215-219, 1986
3. Perelson AS, Essunger P, Cao Y: Decay characteristics of HIV-infected compartments during combination therapy. Nature 387: 188-192, 1997
4. Ho DD, Neumann AU, Perelson AS: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126, 1995
5. Perno CF, Cooney DA, Gao WY, et al.: Effects of bone-marrow stimulatory cytokines on HIV replication and the antiviral activity of dideoxynucleosides in cultures of monocytes/macrophages. Blood 80: 995-1003, 1992
6. Perno CF, Bergamini A, Pesce CD, et al.: Inhibition of the protease of hman immunodeficiency virus blocks replication and infectivity of the virus in chronically-infected macrophages. J Infect Dis 168: 1148-1156, 1993
7. Yarchoan R, Berg G, Perno CF, et al.: Response of human immunodeficiency virus-associated neurological disease to 3′-azido-3′-deoxythymidine. Lancet 1:132-135, 1987
8. Shaw GM, Harper ME, Epstein LG, et al.: HTLV-III infection in brains of children and adults with AIDS encephalopathy. Science 227: 177-181, 1985
9. Koenig S, Gendelman HE, Orenstein JM, et al.: Detection of AIDS virus in macrophages in brain tissues from AIDS patients with encephalopathy. Science 233: 1089-1093, 1987
10. Klecker RW, Collins JM, Yarchoan R, et al.: Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine, a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 41:407-412, 1987
11. Federici ME, Kline MW, Rutkiewicz VL, et al.: A phase I/II evaluation of stavudine (d4T) in children with HIV infection. Int Antiv News4: 109-111, 1996
12. Carpenter CC, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1996. Recommendation of an international panel. International AIDS Society. J Am Med Assoc. 276: 146-154, 1996
13. Gisslen M, Norkrans G, Svennerholm B, et al.: The effect on cerebrospinal fluid HIV-RNA levels after initiation of zidovudine or didanosine. Proc. III Int. Congr. On Drug Ther. In HIV Infect. AIDS 1996 (Suppl. 2) (Abstr. S10)
14. Tsai CC, Follis KE, Sabo A, et al: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270: 1197-1199, 1995
15. Deeks SG, Barditch-Crovo P, Lietman PS, et al.: The safety and efficacy of PMPA prodrug monotherapy: Preliminary results of a Phase I/II dose escalation study. Proc V Conf On Retrov And Opport Infect, Chicago February 1-5, 1998, (Abstr. LB8)
16. Deeks SG, Collier A, Lalezari J, et al.: The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. J Infect Dis 176: 1517-23, 1997
17. Gulick RM, Mellors JW, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739, 1997
18. Mellors JW, Rinaldo CR, Gupta P, et al.: Prognosis of HIV-1 infection predicted by the quantity of virus in plasma. Science 272: 1167-1170, 1996